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Abstract
Background: Metabolic syndrome (MetS) management programs conventionally focus on the adults having MetS.
However, risk assessment for MetS development is also important for many adults potentially at risk but do not yet
fulfill MetS criteria at screening. Therefore, we conducted this follow-up study to explore whether initial screening
records can be efficiently applied on the prediction of the MetS occurrence in healthy middle-aged employees.
Methods: Utilizing health examination data, a five-year follow-up observational study was conducted for 1384
middle-aged Taiwanese employees not fulfilling MetS criteria. Data analyzed included: gender, age, MetS
components, uric acid, insulin, liver enzymes, sonographic fatty liver, hepatovirus infections and lifestyle factors.
Multivariate logistic regression was used to estimate the adjusted odds ratios (OR) and 95% confidence interval (CI)
of risk for MetS development. The synergistic index (SI) values and their confidence intervals of risk factor
combinations were calculated; and were used to estimate the interacting effects of coupling MetS components on
MetS development.
Results: Within five years, 13% (175 out of 1384) participants fulfilled MetS criteria. The ORs for MetS development
among adults initially having one or two MetS components were 2.8 and 7.3, respectively (both p < 0.01), versus
the adults having zero MetS component count at screening. Central obesity carried an OR of 7.5 (p < 0.01), which
far exceeded other risk factors (all ORs < 2.7). Synergistic effects on MetS development existed between coupling
MetS components: 1. High blood pressure plus low-HDL demonstrated an OR of 11.7 (p < 0.01) for MetS
development and an SI of 4.7 (95% CI, 2.1-10.9). 2. High blood pressure plus hyperglycemia had an OR of 7.9 (p <
0.01), and an SI of 2.7 (95% CI, 1.2-6.4).
Conclusion: MetS component count and combination can be used in predicting MetS development for
participants potentially at risk. Worksite MetS screening programs simultaneously allow for finding out cases and for
assessing risk of MetS development.
Background
Metabolic syndrome (MetS) management programs con-
ventionally focused on the adults having MetS [1-3];
while risk assessment for MetS development is also
important for many middle-aged adults potentially at
risk but do not yet fulfill MetS criteria at screening. Risk
assessments for MetS development by utilizing data
from lifestyle investigations [4,5] or MetS components,
such as elevated blood pressure, dyslipidemia and
obesity, have been studied in general population surveys
[6,7]. In terms of multi-functional applications and bud-
get effectiveness for health managements, it is worth to
investigate whether the records, such as MetS compo-
nent measurements, from a MetS screening program
can be further applied on the risk assessment for MetS
development. For the large middle-aged working popu-
lation, however, there is a lack of comprehensive follow-
up survey examining whether 1. The MetS component
count, 2. Each individual MetS component or 3. The
combinations of individual MetS components are asso-
ciated with MetS development. Since periodic routine
health examinations are compulsory for workers at
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observe the development of MetS among middle-aged
employees. Therefore, we conducted this workplace-
based retrospective follow-up study to evaluate whether
the readymade database from the MetS screening pro-
gram is helpful in risk assessment for MetS development
in middle-aged Taiwanese adults.
Methods
Study populations
In accordance with the Labor Health Protection Regula-
tion, 1648 employees from an electricity manufacturing
company underwent compulsory health checkups in
2002 and 2007. The final analysis of this follow-up study
included only the adults who did not fulfill the MetS
criteria in 2002. Among the 1648 workers undergoing
health examinations in both 2002 and 2007, 256
employees’ records were excluded from the present
study because of having MetS in 2002. A total of 1384
adults (338 female and 996 male) constituted a cohort;
and their records were used for endpoint analysis. This
health examination was open to all registered employees
during every working day, for one-month duration. The
examinees were suggested to avoid strenuous physical
exercise during the three-day span prior to undergoing
the health examination. Subjects’ identities were anon-
ymous and unlinked to the data. This analytical study
followed the ethical criteria for human research; the
study protocol (TYGH09702108) was reviewed and
approved by the Ethics Committee of the Tao-Yuan
General Hospital, Taiwan. Written informed consent
was obtained from each participant.
Demographics, lifestyle data, biological measurements
and sonogram examinations
In 2002, a questionnaire about baseline personal history,
including physical exercise, smoking, drinking and diet-
ary habits, was completed by the examinees. Physical
examinations and blood tests were performed on all par-
ticipants in both 2002 and 2007. The participants
arrived at the health care unit of the factory in the
morning between 07:30 and 09:30 AM, after an over-
night 8 h fast. The physical examination records
included measurements of waist circumference, weight,
height, and blood pressure. Waist circumferences were
measured midway between the lowest rib and the super-
ior border of the iliac crest. After being seated for
5=min, sitting blood pressure was measured on the
dominant arm using digital automatic sphygmoman-
ometers (model HEM 907, Omron, Japan) two times at
a 5 min interval; the mean of the reading was used for
data analysis. After the physical examination, partici-
pants were placed in a reclining position, and venous
blood (20 ml) from an antecubital vein of the arm was
taken for subsequent tests. Blood specimens were centri-
fuged immediately thereafter; and shipped frozen in dry
ice to central clinical laboratory (certified by ISO 15189
and ISO 17025) in Tao-Yuan General Hospital. Glucose,
triglyceride, high-density lipoprotein (HDL) cholesterol,
alanine aminotransferase (ALT), g-glutamil transferase
(g-GT) and uric acid analyses were conducted by a Hita-
chi autoanalyzer, model 7150 (Hitachi, Tokyo, Japan).
Hepatitis B virus (HBV) surface antigen (HBsAg) and
anti-Hepatitis C virus (HCV) antibody were measured
by the microparticle enzyme immunoassay using the
Axsym System instrument (Abbott, Illinois, USA). Insu-
lin was determined by radioimmunoassay using an
Axsym autoanalyzer (Abbott, Illinois, USA).
Since sonographic diagnosis for fatty liver has accepta-
ble agreement among operators [8] and is widely
accepted in many epidemiological surveys [9], this non-
invasive method was used to diagnose fatty liver. In
2002, abdominal ultrasound examinations were per-
formed for all examinees using convex-type real-time
electronic scanners (Toshiba SSA-340 with 3.75 MHz
convex-type transducer).
Definitions
We defined “having routine physical exercise” as
answering, “Doing exercises more than three times every
week.” To define “ever been a smoker”, the first ques-
tion was “do you smoke? (1. Never, 2. Currently smoke,
3. Previously smoked, have since quit),” and this was fol-
lowed by questions about frequency. We defined “ever
been a smoker” as answering “yes” to question 2 or 3
and consuming at least 6 cigarettes daily for over one
year. For defining “habitual drinker”, the first question
was “do you usually consume alcohol? (1. No, 2. Yes),”
and this was followed by questions regarding frequency
and quantity; we defined “habitual drinker” in this study
as saying “yes” to previous question and drinking at
least one time weekly, over one year, with alcohol con-
sumption more than 40 g/day for males or 20 g/day for
females [10]. For defining “used to having snacks”,t h e
first questions were “are you used to having snacks
before sleeping?” and “are you used to having snacks
between meals?” These were followed with questions
regarding quantity. We defined snacking habits in the
present study as more than three times per week. The
standard portions of examples for snacks (fruit products,
milk products, fried food, nuts, beans products, meat,
and alternatives) were explained to examinees in
questionnaires.
MetS was diagnosed if the examinees had three or
more of the following components: central obesity
(COB) was identified as a waist circumference > 90 cm
for male and > 80 cm for female; high blood pressure
(HBP) was defined as systolic blood pressure (SBP) ≥
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mmHg. Hyperglycemia (Hyper-GL), hypertriglyceridemia
(Hyper-TG) and low-HDL cholesterolemia (Low-HDL)
were defined as fasting sugar ≥ 100 mg/dL, triglycerides
≥ 150.mg/dL and HDL < 40 mg/dL for males and < 50
for females (Bureau of Health Promotion in Department
of Health, Taiwan) [11,12]. We specified the adults hav-
ing MetS outcomes as those who did not fulfill MetS
criteria in 2002 but did in 2007. Hyperinsulinemia(>
11.6 μU/ml) was arbitrarily defined as the top quartile
level of our analyzed population as in other studies
[13,14]. Elevated ALT (> 40 U/L), g-GT (> 50 U/L) and
hyperuricemia (> 8 mg/dL) were defined as having a
value greater than the normal range established by the
Tao-Yuan General Hospital clinical laboratory [15].
Sonographic fatty liver was assessed using the follow-
ing five parameters: liver-kidney contrast, gall bladder
wall masking, blurring of wall of hepatic and portal
veins, far attenuation of the diaphragm; and diagnosis
was made according to previous reports [16].
Statistical analysis
Baseline characteristics and abnormal rates were com-
pared between subgroups with/without MetS outcome
within five years using the t-test and the c
2 test for cate-
gorical and continual variables as appropriate. Three
models of multivariate logistic regression were used to
estimate the adjusted odds ratio (OR) and 95% confi-
dence intervals (CI) of risk factors for predicting MetS
development, under the adjustments for age, gender,
previously documented predictors of MetS development
(hyperinsulinemia, hyperuricemia, elevated liver enzymes,
and sonographic fatty liver), lifestyle, each MetS compo-
nent, the MetS component count and their combinations.
A two-sided P-value < 0.05 was considered statistically
significant.
The synergistic index (SI) value of potential risk fac-
tors A and B was therefore calculated by following the
mathematical formula. A value of SI > 1.0 indicated that
the interaction was more than an additive interaction,
i.e., synergism [17].
SI
OR A plus B
OR (A alone) OR (alone)
=
−
+−
[( ) ]
[]
1
2
SAS version 8.0 (SAS Institute, Cary, NC, USA) was
used for all statistical analyses.
Results
Within a five-year interval, 13% (175 out of 1384) of the
participants met the criteria of MetS. Table 1 sum-
marizes the overall baseline characteristics and abnorm-
ality rates of the sample population in 2002. The initial
mean age for this population was 32.3 years. Significant
differences were found when grouping baseline data
according to the MetS outcome: as shown in the upper
rows of Table 1, the adults having MetS outcome had
significantly unfavorable initial measurements including
baseline body mass index, waist, blood pressures, blood
sugar, lipid profiles, liver enzymes, uric acid and insulin.
Also shown in the lower rows of Table 1, this was a
male-dominated (72.0%) working population; there were
58.6% participants initially having at least one MetS
components; 26.1% smoked; 7.2% regularly consumed
alcohol at least once a week and 32.1% did exercise at
least three times per week. There were 27.4% of the par-
ticipants having fatty liver. HBV and HCV carriers were
18.5% and 1.2% of sample population, respectively. With
respect to MetS outcome, the adults initially having
MetS components, the males, the habitual drinkers and
the adults having fatty liver significantly prone to have
MetS outcome within five years (Table 1).
The initial prevalence rates of individual MetS compo-
nents and their combinations are shown on Table 2.
Upper rows demonstrate the prevalence of MetS com-
ponents (not segregated from each other): COB, 3.9%;
H y p e r - G L ,2 0 . 5 % ;L o w - H D L ,2 4 . 4 % ;H B P ,1 7 . 7 % ;a n d
Hyper-TG, 13.7%. The initial abnormality rates of each
component were significantly unfavorable for the adults
having MetS outcome. Table 2 also shows that the base-
line prevalence rate of single MetS component was
36.9%; and that 21.7% of sample population had two
MetS components. Among the adults initially having
only one MetS component, baseline distributions of
each single MetS component were non-significantly dif-
ferent between the groups with/without MetS outcome
(Table 2, middle rows). In contrast, the adults initially
having two MetS components predominated signifi-
cantly in the group having MetS outcome (Table 2,
lower rows).
A ss h o w ni nT a b l e3 ,4a n d5w ec o n s t r u c t e dt h r e e
models for the multivariate analyses. Utilizing a conven-
tional model, after controlling for confounders, Table 3
demonstrates that MetS components, sonographic fatty
liver, elevated g-GT and hyperinsulinemia were indepen-
dent risk factors for MetS development among our
early-middle-aged employees. Table 3 also indicates that
the middle-aged adults getting central obesity had an
OR of 7.5 (p < 0.01), which was far ahead of other indi-
vidual risk factors (ORs ≤ 2.7). Taking MetS component
count as a potential risk factor in model 2, Table 4
shows that adults having single and double MetS com-
ponent had respectively a 2.8-fold (95% CI, 1.6-4.7) and
7.3-fold (95% CI, 4.3-12.6) increased risk of progression
to MetS, compared with adults initially having zero
MetS component count. In model 3 (Table 5), the entire
single and two MetS component-carrying statuses,
totally fifteen isolated assortments were introduced.
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0.05) of two-component combinations were greater than
the ORs of single components except for COB-alone
(OR, 9.1, p < 0.01). Among the two-component combi-
nations, synergistic effects on MetS development were
found in following combinations: HBP-plus-Low-HDL
with OR of 11.7(p < 0.01), and HBP-plus-hyperglycemia
with OR of 7.9 (p < 0.01) for MetS development com-
pared with the adults having zero MetS component
count, synergistic indexes were 4.7 (95% CI, 2.1-10.9)
and 2.7 (95% CI, 1.2-6.4), respectively.
Discussion and Conclusions
At the baseline screening for MetS among our middle-
aged working population, 84% (1384 from 1640) of the
employees did not fulfill MetS criteria. However, within
five years, a considerable number (13%, 175 from 1384)
of the middle-aged workers fulfilled criteria of MetS.
The incidence of MetS in our middle-aged working
population was as high as reported in a survey for Chi-
nese middle-aged adults [18]. Risk evaluations for MetS
development in general population had attracted
attentions of public health professionals [4-7]; further-
more, risk assessments for MetS development are also
necessary for all middle-aged adults, including the early-
middle-aged adults potentially at risk, but not yet fulfill-
ing MetS criteria at screening. In a previous worksite
MetS research, applying a health promotion program for
high-risk persons, Richard V. and colleagues obtained
decreased total health risk as well as markedly reduced
medical claim costs; and finally, over half of all baseline
high-risk persons were converted to low-risk statuses
[19]. In terms of health management, our results can
help use the readymade screening records to identify
high-risk adults and start intervention as soon as
possible.
Initially, over half of the adults from our sample popu-
lation had at least one MetS component (58.6%, Table 1;
36.9% with single and 21.7% with two components,
Table 2). Our follow-up survey demonstrated a signifi-
cant correlation between the baseline MetS component
count and MetS development. The middle-aged adults
having one or two MetS components had respectively
2.8-fold and 7.3-fold increased risks for developing MetS
Table 1 Baseline characteristics for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially
2002 baseline data, divided by MetS outcome in 2007**
Variable* Overall N = 1384 Without MetS outcome With MetS outcome P
n = 1209 n = 175
Age (years) 32.3 ± 6.5 32.1 ± 6.5 33.3 ± 6.6 0.04
Body mass index (kg/m
2) 23.0 ± 3.0 22.6 ± 2.9 25.8 ± 2.5 <0.01
Waist (cm) 75.6 ± 8.6 74.4 ± 8.2 83.3 ± 7.4 <0.01
Systolic blood pressure (mmHg) 117.0 ± 14.3 116.0 ± 14.1 124.2 ± 14.2 <0.01
Diastolic blood pressure(mmHg) 71.7 ± 9.2 71.0 ± 9.0 76.4 ± 9.0 <0.01
Fasting blood sugar (mg/dl) 94.3 ± 13.2 93.7 ± 12.0 97.8 ± 19 6 <0.01
Triglyceride (mg/dl) 102.5 ± 78.0 97.3 ± 77.3 137.9 ± 73.3 <0.01
HDL cholesterol (mg/dl) 50.5 ± 11.8 51.2 ± 11.7 46.0 ± 12.0 <0.01
Alanine aminotransferase (U/l) 27.2 ± 26.6 25.5 ± 25.8 38.5 ± 29.3 <0.01
g-Glutamyl transferase (U/l) 33.4 ± 24.7 31.0 ± 22.2 49.7 ± 33.3 <0.01
Uric acid (mg/dl) 6.6 ± 1.6 6.5 ± 1.6 7.2 ± 1.5 <0.01
Insulin (μU/ml) 8.2 ± 5.7 7.8 ± 5.0 11.1 ± 8.9 <0.01
Adults having MetS component (count ≤ 2) 811 (58.6%) 657 (54.3%) 154 (88.0%) <0.01
Male gender 996 (72.0%) 855 (70.7%) 141(80.6%) <0.01
Ever been a smoker (≥ 6 cigarettes/day for ≥1 year) 361 (26.1%) 312 (25.8%) 49 (28.0%) 0.55
Regular alcohol consumption (≥ 1 day/week) 100 (7.2%) 77 (6.4%) 23 (13.1%) 0.01
Taking exercise ≥ 3 days/week) 444 (32.1%) 389 (32.2%) 55 (31.4%) 0.84
Having snacks before sleeping (≥ 3 days/week) 644 (46.5%) 568 (47.0%) 76 (43.4%) 0.38
Having snacks between meals (≥ 3 days/week) 546 (39.5%) 473 (39.1%) 73 (41.7%) 0.51
HBV carrier 256 (18.5%) 221 (18.3%) 35 (20.0%) 0.59
HCV carrier 16 (1.2%) 13 (1.1%) 3 (1.7%) 0.53
Sonographic fatty liver 349 (27.4%) 278 (23.0%) 101 (57.7%) <0.01
* The upper rows are means and standard deviation (mean ± SD), and the lower rows are proportions (numbers and proportions,%). Abbreviations: HDL
cholesterol, high-density lipoprotein cholesterol.
** t-tests for continual variables between groups with/without MetS outcome; c
2 tests were conducted for categorical variables between groups with/without
MetS outcome
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initially
2002 baseline data, divided by MetS outcome in 2007**
Abnormality Prevalence* Overall
N = 1384
Without MetS outcome n = 1209 With MetS outcome, n = 175 P
MetS component (not segregated)
COB 54 (3.9%) 28 (2.3%) 26(14.9%) <0.01
Hyper-GL 284 (20.5%) 234 (19.4%) 50(28.6%) 0.01
HBP 245 (17.7%) 193 (16.0%) 52(29.7%) <0.01
Low-HDL 338 (24.4%) 269 (22.2%) 69(39.4%) <0.01
Hyper-TG 190 (13.7%) 139 (11.5%) 51(29.1%) <0.01
MetS component (segregated by count and combination)
Single component 511 (36.9%) 451 (37.3%) 60 (34.3%) 0.44
Hyper-GL alone 149 (10.8%) 132 (10.9%) 17(9.7%) 0.62
Low-HDL alone 168 (12.1%) 151 (12.5%) 17(9.7%) 0.27
HBP alone 115 (8.3%) 107 (8.9%) 8(4.6%) 0.02
Hyper-TG alone 63 (4.6%) 51 (4.2%) 12(6.9%) 0.19
COB alone 16 (1.2%) 10 (0.8%) 6(3.4%) 0.07
Two components 300 (21.7%) 206 (17.0%) 94 (53.7%) <0.01
Low-HDL-plus-Hyper-TG 61 (4.4%) 43 (3.6%) 18(10.3%) <0.01
Hyper-GL-plus-Low-HDL 51 (3.7%) 42 (3.5%) 9(5.1%) 0.34
Low-HDL-plus-HBP 42 (3.0%) 26 (2.2%) 16(9.1%) <0.01
Hyper-TG-plus-HBP 31 (2.2%) 22 (1.8%) 9(5.1%) 0.05
Hyper-GL-plus-Hyper-TG 30 (2.2%) 22 (1.8%) 8(4.6%) 0.09
COB-plus-Low-HDL 16 (1.2%) 7 (0.6%) 9(5.1%) <0.01
COB-plus-HBP 10 (0.7%) 5 (0.4%) 5(2.9%) 0.06
COB-plus-Hyper-GL 7 (0.5%) 5 (0.4%) 2(1.1%) 0.38
COB-plus-Hyper-TG 5 (0.4%) 1 (0.1%) 4(2.3%) 0.05
* The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or
two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed.
Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
**c
2 tests were conducted for categorical variables between groups with/without MetS outcome.
Table 3 Model 1, adjusted risks for metabolic syndrome
(MetS), conventionally, individual MetS-components are
not separated apart
Baseline potential risk factors* Adjusted-OR** 95%CI p
MetS component
COB 7.5 4.0 – 14.2 <0.01
Hyper-TG 2.4 1.5 – 3.7 <0.01
Hyper-GL 2.2 1.4 – 3.3 <0.01
Low-HDL 2.7 1.8 – 4.0 <0.01
HBP 2.5 1.6 – 3.9 <0.01
Hyperuricemia 1.0 0.6 – 1.6 0.98
Sonographic fatty liver 2.3 1.6 – 3.5 <0.01
Elevated alanine aminotransferase 1.3 0.8 – 2.1 0.36
Elevated g-glutamil transferase 2.0 1.3 – 3.1 <0.01
Hyperinsulinemia 1.7 1.1 – 2.6 <0.01
* Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL
cholesterolemia; HBP, High blood pressure; Hyper-TG, hypertriglyceridemia;
COB, central obesity
** Adjusted variables were age and categorical variables including gender,
smoking, diet habits, drinking, exercise status, sonographic liver enzymes, fatty
liver, hepatovirus infections, hyperinsulinemia and hyperuricemia.
Table 4 Model 2, adjusted risks for metabolic syndrome
(MetS) using MetS-component count as potential risk
factors
Baseline potential risk factors Adjusted-OR* 95%CI p
MetS component count
Adults having a single MetS
component
2.8 1.6 – 4.7 <0.01
Adults having two MetS
components
7.3 4.3 – 12.6 <0.01
Hyperuricemia 1.0 0.6 – 1.6 0.99
Sonographic fatty liver 2.4 1.6 – 3.6 <0.01
Elevated alanine aminotransferase 1.3 0.8 – 2.1 0.37
Elevated g-glutamyl transferase 2.0 1.2 – 3.1 <0.01
Hyperinsulinemia 1.8 1.2 – 2.6 <0.01
* Adjusted variables were age and categorical variables including gender,
smoking, diet habits, drinking, exercise status, liver enzymes, sonographic fatty
liver, hepatovirus infections, hyperinsulinemia and hyperuricemia.
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component count (Table 4). Some cardiovascular disease
(CVD)-related surveillance studies had similar findings:
the MetS component count has been associated with
CVD occurrence [20], mortalities [21] and important sur-
rogate markers [22]. Furthermore, Schultz and Edington
demonstrated that changes in MetS component count
were significantly related to the medical costs for work-
forces [23]. As a relatively simple measurement, we sug-
gest using the MetS component count as a fundamental
item for risk assessment in MetS management programs.
Throughout our analyses, central obesity was the stron-
gest predictor for MetS development out of all risk factors
(Table 3 and Table 5), regardless of its combinations with
any other individual risk factors (Table 5). Since the “yo-
yo” effects appeared in many trials for weight reduction
[24], our observation support that prevention for obesity
should be strongly prioritized for middle-aged adults in
terms of MetS prevention [25]. Previous investigations and
our current analyses both agreed that elevated g-GT [26],
hyperinsulinemia [27] and sonographic fatty liver [28] are
all acceptable predictors for MetS development. However,
according to our multivariate analysis (Table 3, Table 4),
the ORs of the risk factors mentioned above were not sig-
nificantly greater than ORs of MetS components. On the
other hand, all measurements of MetS components are
available in most medical settings [29], in contrast to
many equipment-requiring image examinations or techni-
que-dependent measurements of surrogate markers
[30-33]. Such a relatively accessible program capable of
making its contributions simultaneously to abnormality
screening and effective risk assessments, MetS screening
program naturally has an important aspect of public health
promotion.
Our component-component interaction analyses
demonstrated several significant compound effects of
MetS components on MetS development. In our two-
component analyses, the middle-aged adults simulta-
neously having HBP and any other MetS component
were at a dramatically increased risk for MetS develop-
ment (model 3, Table 5, lower rows). The results of the
analyses for MetS development were relatively close to
clinical observations: together with other risk factors,
hypertension had aggravating effects on the cardiovascu-
lar risks [34]. In addition, high blood pressure clustered
with raised blood glucose or low HDL cholesterol were
the riskiest combinations for arterial disease or prema-
ture death [35,36]. Health managers should emphasize
blood pressure control in workplace-based MetS man-
agement programs because of its high abnormality rate
among the middle-aged population and its synergistic
interactions with other risk factors.
The major limitation of this observational investiga-
tion is that we did not take into consideration potential
Table 5 Model 3, adjusted risks for metabolic syndrome (MetS) calculated using each MetS component and their
combinations as potential risk factors
Baseline MetS components and combinations* Adjusted-OR** 95%CI Overall (N = 1384)
P
SI
† 95%CI
Adults having single MetS component at baseline NA
‡ -- - -
COB alone 9.1 2.8 - 29.9 <0.01 one risk alone -
Hyper-TG alone 3.4 1.5 - 7.7 <0.01 one risk alone -
Hyper-GL alone 3.0 1.5 - 6.0 <0.01 one risk alone -
Low-HDL alone 2.9 1.4 - 5.8 <0.01 one risk alone -
HBP alone 1.4 0.6 - 3.4 0.44 one risk alone -
Adults having two MetS components at baseline NA
COB-plus-Hyper-TG 59.6 5.8 - 611.5 <0.01 7.6 0.8 - 74.5
COB-plus-Low-HDL 24.6 7.7 - 78.2 <0.01 2.8 0.8 - 9.2
COB-plus-HBP 14.5 3.6 - 59.1 <0.01 2.0 0.5 - 8.5
HBP-plus-Low-HDL 11.7 5.1 - 27.0 <0.01 4.7 2.1 - 10.9
HBP-plus-Hyper-GL 7.9 3.5 - 18.1 <0.01 2.7 1.2 - 6.4
COB-plus-Hyper-GL 6.7 1.2 - 38.7 <0.05 0.8 0.1 - 5.2
HBP-plus-Hyper-TG 5.8 2.2 - 15.4 <0.01 1.6 0.6 - 4.3
Low-HDL-plus-Hyper-TG 5.7 2.7 - 12.3 <0.01 1.6 0.7 - 3.3
Hyper-GL-plus-Hyper-TG 4.1 1.5 - 11.1 <0.01 1.6 0.6 - 4.4
Hyper-GL-plus-Low-HDL 3.9 1.6 - 9.8 <0.01 1.1 0.4 - 2.9
* Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
** Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, liver enzymes, sonographic fatty liver,
hepatovirus infections, hyperinsulinemia and hyperuricemia.
† SI, synergistic index, SI value exceeding 1.0 indicates the presence of synergistic interaction.
‡ NA: Not analyzed in this model, analyzed and shown in Table 4, Model 2.
SI and 95%CI in bold are considered to be statistically significant.
Lin et al. BMC Public Health 2010, 10:747
http://www.biomedcentral.com/1471-2458/10/747
Page 6 of 8treatment effects. For some persons with one or two
MetS components, it was possible that they could have
utilized corrective options including lifestyles changes
[37] or medications such as antihypertensive [38] or
lipids lowering agents [39]. Those actions might lead to
protective effects [40], and therefore, the true risk of
MetS development might be underestimated in this
early-middle-aged population. Naturally, this is a work-
place follow-up survey for relatively healthy workers.
Thus, the application of our conclusions to the general
population should be cautious. On the other hand, sta-
tistically, our findings of MetS component combinations
were based on low case numbers, which might have
resulted in a low number bias. Thus, larger sample
population studies are needed in the future.
In sum, a workplace-based MetS screening program
simultaneously allows for finding out cases and for asses-
sing risk of MetS development. MetS component count
and combination can be used in predicting MetS devel-
opment for participants potentially at risk. For MetS pre-
vention, any increase in the number of MetS components
should be avoided. Since central obesity plays a pivotal
role and high blood pressure synergistically potentiates
other risk factors toward MetS development, efforts to
address these two easily measurable risk factors must be
prioritized in workplace MetS management programs.
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